-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
How does the human body fight tumor formation? The human immune system includes a variety of immune cells, among which type 1 conventional dendritic cells (cDC1) are essential for effective anti-tumor immunity
The interference of cDC1 recruitment in cancer has become a means to evade the body's immunity, and increasing the recruitment, survival, expansion and functional activity of cDC1 in the tumor microenvironment (TME) has anti-tumor effects
On June 2, 2021, the international academic journal "Cell" published an online study titled "Secreted gelsolin inhibits DNGR-1-dependent cross-presentation and cancer immunity" by the Caetano Reis e Sousa team of the Francis Crick Institute in the United Kingdom
The researchers proposed that cDC1 expresses a high level of c-type lectin receptor DNGR-1 (also known as CLEC9A), which can bind to F-actin exposed on the surface of necrotic cells to promote the cross-transmission of dead cell antigens
Researchers found that fetal calf serum (FCS) has an inhibitory effect on the binding of DNFR-1 to F-actin, while FCS after F-actin treatment and high-speed centrifugation loses this function
Subsequently, the researchers constructed a sGSN-/- mouse model and found that the serum of sGSN-/- mice could not inhibit the binding of DNGR-1 and F-actin.
Inhibition of sGSN on the binding of DNGR-1 and F-actin
Researchers speculate that sGSN-/- mice have increased anti-tumor CD8+ T cell responses
Loss of sGSN impairs tumor growth and enhances response to immunotherapy
Combining the results of the above animal experiments, the researchers speculate that in humans, certain cancers are also related to sGSN
Subsequently, the researchers tested the expression of F-actin binding proteins (FABPs) in patients with LIHC, HNSC and STAD, and further grouped patients according to the level of sGSN transcription in the tumor
Low sGSN levels are correlated with the survival of patients with high CLEC9A expression
In general, this study clarified that sGSN is a previously undiscovered tumor immune evasion-related factor
Therefore, transient targeting of the interaction between sGSN and F-actin may be a safe and effective tumor immunotherapy strategy
Reference materials:
[1]https://
